October 13, 2018

BNTC: Benitec Biopharma Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	265.00
Enterprise Value ($M)	186.72
Book Value ($M)	75.94
Book Value / Share	3.24
Price / Book	3.49
NCAV ($M)	75.59
NCAV / Share	3.22
Price / NCAV	3.51

Profitability (mra)
Return on Invested Capital (ROIC)	-0.28
Return on Assets (ROA)	-1.00
Return on Equity (ROE)	-1.38

Liquidity (mrq)
Quick Ratio	25.48
Current Ratio	25.48

Balance Sheet (mrq) ($M)
Current Assets	78.71
Assets	79.07
Liabilities	3.13
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	-22.49
Net Income	-21.75
Earnings Per Share Basic And Diluted	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	-19.40
Cash from Investing	-0.18
Cash from Financing	68.03
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
02-14	13G/A	Janus Henderson Group Plc
02-13	13G/A	HBM Healthcare Investments (Cayman) Ltd.
01-27	13G/A	Franklin Resources Inc
11-18	13D/A	Suvretta Capital Management, Llc	49.90	62.30
11-14	13G	Nantahala Capital Management, LLC
04-11	13G/A	Adage Capital Partners Gp, L.l.c.	9.99	39.81
2024-02-14	13G/A	Citadel Advisors Llc	3.60

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2025-02-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect
2024-05-13	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-02-24	5,310	52,313	10.15
2025-02-21	2,678	13,722	19.52
2025-02-20	3,714	17,972	20.67
2025-02-19	1,190	9,750	12.21
(click for more detail)

Similar Companies
BGM – BGM Group Ltd.	BIVI – BioVie Inc.
BMRA – Biomerica, Inc.	BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited

Financial data and stock pages provided by
Fintel.io

Related